C
Tier
Potent ghrelin-receptor GH-releasing peptide.
Muscle & Performance
Peptide
WADA Status:
Prohibited at all times (S2)
Human Trial Scoreboard
Completed human RCTs
Count not verified
Largest Human Study
Size not verified
Longest exposure
Duration not verified
Most Recent Trial
Year not verified
Description
GHRP-2, also called pralmorelin, is a ghrelin-receptor agonist that prompts growth hormone release. It has a slightly more respectable history than its siblings because it has been used clinically as a diagnostic agent in some countries, giving doctors a way to test whether a patient's pituitary responds normally. That is a very different use from the one it is marketed for online. It is frequently discussed interchangeably with GHRP-6, which is a mistake worth correcting: the two differ meaningfully in how strongly they stimulate appetite. No trial has demonstrated that raising growth hormone this way improves body composition, strength or recovery in healthy people, and it has never been approved for any consumer use.
What Are The Claims
Claims made for this compound: Reliable GH release, synergistic with GHRH analogs; Increases appetite, sometimes used intentionally; Established as a GH diagnostic
Evidence
Reliably stimulates GH release in human studies. No outcome data for the physique or recovery uses it is marketed for.
Evidence Strength
Preliminary (human GH/diagnostic data)
Caveats
Not approved as therapy in the US; raises cortisol and prolactin; no long-term outcome trials.
Safety
Alternative Measures
Legal Status
US
Not approved
UK
Not approved
EU
Not approved
AU
Not approved
WADA
Prohibited at all times (S2)
Not approved for general use. Research chemical; has been used as a diagnostic agent in some countries. WADA-prohibited.
Citations
Human GH-secretion studies; used as a GH-provocative diagnostic agent.